News

The FDA has approved a new maintenance dosing schedule for Ebglyss that reduces injections to as few as six per year for patients with moderate to severe atopic dermatitis.

An electronic health record–based model could help health systems target diabetes prevention to the high-risk patients most likely to benefit.

The REIMAGINE 1, 2 and 3 trials each met their primary HbA1c end point and confirmatory secondary end points for body weight reduction.

An individualized mRNA neoantigen vaccine added to pembrolizumab reduced the risk of recurrence by 49% and distant metastasis by 59% in resected high-risk melanoma, with benefits holding through five years of follow-up in a phase 2b trial.

Nearly half of payers not covering GLP-1s for obesity say no price would change their minds on coverage, citing high costs, poor adherence, and weight regain concerns, finds a new survey by PSG.

Cambridge researchers have completed the first human trial of pEVAC-PS, an AI-designed vaccine intended to protect against the entire family of Sarbeco viruses, finding it safe and well tolerated across all dose levels, with modest immune responses that warrant further investigation in a phase 2 trial.

A decision on Alvotech’s BLA for AVT16 could come as soon as the first quarter of 2027, but Entyvio’s patent doesn’t expire until 2032.

The experimental glucagon/GLP-1 dual agonist showed targeted reductions in metabolically harmful fat alongside meaningful weight loss in two distinct patient populations.

As value-based care continues to evolve, models that embed physician input into decision-making, align incentives and maintain transparency are more likely to sustain improvement.

The first triple hormone receptor agonist to reach phase 3 development demonstrated results that researchers say could reshape how clinicians approach obesity and type 2 diabetes treatment.

Results presented at ADA 2026 mark the first Level A evidence supporting CGM use in this population.

Joanne Mortimer, M.D., of City of Hope breaks down new data linking GLP-1 receptor agonist use to a reduction in mortality across multiple tumor types.

A new telehealth app called Informed Pain Care connects patients with licensed clinicians for acute pain evaluation and access to treatments nationwide.

Shame, fueled by stigma, can deter care for HIV patients; recognizing it and responding compassionately can reduce harm, according to Abigail Bachelder, M.P.H., Ph.D., associate psychiatry professor at Boston University Chobanian & Avedisian School of Medicine.

Abigail Batchelder, M.P.H., Ph.D., clinical psychologist and associate professor at Boston University, explains the effect that shame can have on the healthcare outcomes of HIV patients and why “explicit compassion” is a step in the right direction when treating these individuals.

Romidepsin is approved to treat adults with cutaneous T-cell lymphoma. Ameal’s generic has received designation for 180 days of exclusivity.

Blood-based tests are less sensitive but might increase adherence.

A newly developed prognostic model may help clinicians better estimate survival in patients with non-small cell lung cancer and brain metastases treated with immune checkpoint inhibitors.

By partnering with pastors to navigate religious taboos and collaborating with public health agencies, researchers Jannette Berkley-Patton, Ph.D., and Kathryn Derose, Ph.D., demonstrated that African American churches — long-standing pillars of their communities — can serve as trusted, effective sites for HIV testing that reach not only congregants but also the broader community, helping to address the disproportionate impact of HIV on African Americans.

Tanya Dorff, M.D., breaks down early ABBV-969 data showing strong responses in heavily pretreated mCRPC at ASCO 2026.

Hospital pharmacy leaders cite a potential rebate model transition for the 340B program as one of their biggest worries amid rising manufacturer restrictions and evolving federal compliance requirements.

The workforce challenge in healthcare is not going away. Health systems and health plans can cope with it by rethinking how work can be divided between humans and artificial intelligence.

The FDA has approved Epiduo for over-the-counter use, a combination acne gel previously available only by prescription, a decision experts say could expand access to effective treatment for the millions of Americans who face cost and logistical barriers to dermatological care.

Real-world data presented at ASCO also show that at 12 month and 24 months, patients treated with Brukinsa had a higher probability of survival than those treated with other BTK inhibitors.

Peterson Philanthropies announced a commitment of $50 million to set up the public benefit company that will provide employers with healthcare pricing and quality data.

C. Brooke Adams, Pharm.D., BCOP, of Orlando Health discusses bispecific antibody therapies for multiple myeloma.

Mike Badome is chief actuary of Arcadia, an outcomes company that helps healthcare organizations improve cost, quality and operational performance.

Bahar Davidoff, Pharm.D., MBA, is founder and principal of Davidoff Strategy and Consulting, a healthcare advisory firm focused on healthcare operations, pharmacy strategy and artificial intelligence (AI) integration.